| Polymorphism of peroxisome proliferator-activated receptor γ (PPARγ) Pro12Ala in the Iranian population: Relation with insulin resistance and response to treatment with pioglitazone in type 2 diabetes. | |
| | |
MedLine Citation:
|
PMID: 21968139 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
The peroxisome proliferator-activated receptor γ (PPARγ) has important effects on insulin sensitivity, obesity and diabetes. Pioglitazone improves insulin sensitivity by activating PPARγ. In view of inter-individual variability in therapeutic response to pioglitazone, this study was designed to search for an association between type 2 diabetes mellitus and Pro12Ala single-nucleotide polymorphism (SNP) in PPARγ (SNP rs1801282) and to investigate whether these genetic variants affect pioglitazone response in an Iranian population. A total of 101 patients with type 2 diabetes were treated for 12weeks with pioglitazone (15mg/day). Paraclinical parameters were measured before and after therapy. We genotyped 128 control participants without diabetes and all patients with type 2 diabetes. The Pro12Ala polymorphism in PPARγ was detected with real-time PCR. The Ala allele was found in 7% of the control participants vs. 3% of those with type 2 diabetes (P=0.04). The genotypic frequencies of Pro/Ala were 14.06% in the former group vs. 5.94% in the latter (P=0.036). There were significant changes in some laboratory values and biochemical markers of insulin sensitivity after pioglitazone therapy. The Pro12Ala polymorphism was associated with significant changes in insulin-to-glucose ratio after treatment (P=0.015 and P=0.005). Our findings suggest that in carriers of the 12Ala variant, pioglitazone significantly reduced the risk of type 2 diabetes, and in diabetic patients with the Pro12Ala genotype, the therapeutic response to treatment was better than in patients with the Pro12Pro genotype, although the difference between groups did not reach statistical significance. |
| | |
Authors:
|
Fatemeh Namvaran; Negar Azarpira; Parvaneh Rahimi-Moghaddam; Mohammad Hossein Dabbaghmanesh |
Related Documents
:
|
18080249 - Two-color electrophoretic immunoassay for simultaneous measurement of insulin and gluca... 7628689 - Circulating catecholamine and glucose concentrations in japanese toads (bufo japonicus)... 1891339 - Modification of liver cell volume by insulin and glucagon. 20381509 - Glucagon regulation of energy metabolism. 3896839 - Glucagon and insulin release in totally gastrectomized rats. 9548399 - Insulin and glucagon secretion by ganglionic nicotinic activation in adrenalectomized m... 19337019 - The investigation of the efficacy of insulin glargine on glycemic control when combined... 19949889 - Fasting plasma glucose in the screening for type 2 diabetes in morbidly obese subjects. 15966559 - Pathogenesis and management of diabetic dyslipidemia. |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-9-24 |
Journal Detail:
|
Title: European journal of pharmacology Volume: - ISSN: 1879-0712 ISO Abbreviation: - Publication Date: 2011 Sep |
Date Detail:
|
Created Date: 2011-10-4 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 1254354 Medline TA: Eur J Pharmacol Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Copyright Information:
|
Copyright © 2011. Published by Elsevier B.V. |
Affiliation:
|
Department of Pharmacology, College of Medicine, Tehran University of Medical Sciences, Tehran, Iran. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Lysophosphatidic acid induces a migratory phenotype through a crosstalk between RhoA-Rock and Src-FA...
Next Document: Involvement of the dopaminergic receptors of the rat basolateral amygdala in anxiolytic-like effects...